138 related articles for article (PubMed ID: 38694505)
1. Efficacy and safety of different immunotherapies combined with chemotherapy as first-line therapy in patients with small cell lung cancer: a network meta-analysis.
Gong S; Li Q; Yu X; Yang S
Front Immunol; 2024; 15():1362537. PubMed ID: 38694505
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of first-line immunotherapy plus chemotherapy in treating patients with extensive-stage small cell lung cancer: a Bayesian network meta-analysis.
Zhang T; Li W; Diwu D; Chen L; Chen X; Wang H
Front Immunol; 2023; 14():1197044. PubMed ID: 37435087
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of first-line immune checkpoint inhibitors combined with chemotherapy for extensive-stage small cell lung cancer: A network meta-analysis.
Wang S; Li Y; Liu Z; Tian W; Zeng Y; Liu J; Zhang S; Peng Y; Wu F
Lung Cancer; 2023 Apr; 178():47-56. PubMed ID: 36774774
[TBL] [Abstract][Full Text] [Related]
4. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
5. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
6. A systematic review and network meta-analysis of first-line immune checkpoint inhibitor combination therapies in patients with advanced non-squamous non-small cell lung cancer.
Shao T; Zhao M; Liang L; Tang W
Front Immunol; 2022; 13():948597. PubMed ID: 36389713
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of novel immune checkpoint inhibitor-based combinations versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer: A network meta-analysis.
Yang C; Xuan T; Gong Q; Dai X; Wang C; Zhang R; Zhao W; Wang J; Yue W; Li J
Thorac Cancer; 2024 May; 15(15):1246-1262. PubMed ID: 38623838
[TBL] [Abstract][Full Text] [Related]
8. Comparison of atezolizumab, durvalumab, pembrolizumab, and nivolumab as first-line treatment in patients with extensive-stage small cell lung cancer: A systematic review and network meta-analysis.
Chen J; Wang J; Xu H
Medicine (Baltimore); 2021 Apr; 100(15):e25180. PubMed ID: 33847617
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of neoadjuvant immunotherapy plus chemotherapy followed by adjuvant immunotherapy in resectable non-small cell lung cancer: a meta-analysis of phase 3 clinical trials.
Zhang W; Liang Z; Zhao Y; Li Y; Chen T; Li W; Chen Y; Wu P; Zhang H; Fang C; Li L
Front Immunol; 2024; 15():1359302. PubMed ID: 38646542
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis.
Li Y; Liang X; Li H; Chen X
Chin Med J (Engl); 2023 Sep; 136(18):2156-2165. PubMed ID: 37596898
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and safety of first-line immune checkpoint inhibitors for patients with extensive-stage small cell lung carcinoma: A systematic review and network meta-analysis.
Du J; Wang X; Fan L; Shan X; Li M; Liu L
Heliyon; 2023 Apr; 9(4):e14794. PubMed ID: 37095958
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Efficacy and Safety of Single and Double Immune Checkpoint Inhibitor-Based First-Line Treatments for Advanced Driver-Gene Wild-Type Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.
Xu Q; Zhang X; Huang M; Dai X; Gao J; Li S; Sheng L; Huang K; Wang J; Liu L
Front Immunol; 2021; 12():731546. PubMed ID: 34484242
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of PD-1/PD-L1 inhibitor plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small cell lung cancer: A systematic review and meta-analysis.
Zhang S; Li S; Cheng Y
Thorac Cancer; 2020 Dec; 11(12):3536-3546. PubMed ID: 33058504
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the efficacy and safety in the treatment strategies between chemotherapy combined with antiangiogenic and with immune checkpoint inhibitors in advanced non-small cell lung cancer patients with negative PD-L1 expression: A network meta-analysis.
Li J; Chen Y; Hu F; Qiang H; Chang Q; Qian J; Shen Y; Cai Y; Chu T
Front Oncol; 2022; 12():1001503. PubMed ID: 36523992
[TBL] [Abstract][Full Text] [Related]
15. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the efficacy and safety of first-line treatments for of advanced EGFR mutation-positive non-small-cell lung cancer in Asian populations: a systematic review and network meta-analysis.
Chen W; Miao J; Wang Y; Xing W; Xu X; Wu R
Front Pharmacol; 2023; 14():1212313. PubMed ID: 37484016
[No Abstract] [Full Text] [Related]
17. Immune checkpoint inhibitors for first-line treatment of advanced non-small-cell lung cancer: A systematic review and network meta-analysis.
Peng TR; Lin HH; Tsai FP; Wu TW
Thorac Cancer; 2021 Nov; 12(21):2873-2885. PubMed ID: 34545685
[TBL] [Abstract][Full Text] [Related]
18. A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer.
Yan YD; Cui JJ; Fu J; Su YJ; Chen XY; Gu ZC; Lin HW
Front Immunol; 2021; 12():760737. PubMed ID: 34925331
[TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy and safety of licensed treatments for previously treated non-small cell lung cancer: A systematic review and network meta-analysis.
Armoiry X; Tsertsvadze A; Connock M; Royle P; Melendez-Torres GJ; Souquet PJ; Clarke A
PLoS One; 2018; 13(7):e0199575. PubMed ID: 30044785
[TBL] [Abstract][Full Text] [Related]
20. Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial.
Cheng Y; Han L; Wu L; Chen J; Sun H; Wen G; Ji Y; Dvorkin M; Shi J; Pan Z; Shi J; Wang X; Bai Y; Melkadze T; Pan Y; Min X; Viguro M; Li X; Zhao Y; Yang J; Makharadze T; Arkania E; Kang W; Wang Q; Zhu J;
JAMA; 2022 Sep; 328(12):1223-1232. PubMed ID: 36166026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
